BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20718720)

  • 1. Use of Cervista HPV HR assay for detection of human papillomavirus in samples with hybrid capture borderline negative results.
    Galan-Sanchez F; Rodriguez-Iglesias MA
    APMIS; 2010 Sep; 118(9):681-4. PubMed ID: 20718720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off.
    Boehmer G; Wang L; Iftner A; Holz B; Haedicke J; von Wasielewski R; Martus P; Iftner T
    BMC Infect Dis; 2014 Dec; 14():674. PubMed ID: 25487281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
    Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
    J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Aptima and Cervista tests for detection of high-risk human papillomavirus in cervical cytology specimens.
    Nolte FS; Ribeiro-Nesbitt DG
    Am J Clin Pathol; 2014 Oct; 142(4):561-6. PubMed ID: 25239425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of the cervista and hybrid capture 2 methods in detecting high-risk human papillomavirus in cervical lesions.
    Tao K; Yang J; Yang H; Guo ZH; Hu YM; Tan ZY; Zhang F; Duan JL
    Diagn Cytopathol; 2014 Mar; 42(3):213-7. PubMed ID: 23904341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
    Poljak M; Kovanda A; Kocjan BJ; Seme K; Jancar N; Vrtacnik-Bokal E
    Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):94-103. PubMed ID: 19784522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cervista HPV HR test for cervical cancer screening: a comparative study in the Catalonian population.
    Alameda F; Garrote L; Mojal S; Sousa C; Muset M; LLoveras B; Bellosillo B; Saldanha C; Carreras R; Serrano S
    Arch Pathol Lab Med; 2015 Feb; 139(2):241-4. PubMed ID: 25611107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Validation of Anyplex II HPV HR Detection Test for Cervical Cancer Screening in Korea.
    Jung S; Lee B; Lee KN; Kim Y; Oh EJ
    Arch Pathol Lab Med; 2016 Mar; 140(3):276-80. PubMed ID: 26927723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of careHPV, Cervista Human Papillomavirus, and Hybrid Capture 2 Methods in Diagnosing Cervical Intraepithelial Neoplasia Grade 2+ in Xinjiang Uyghur Women.
    Tuerxun G; Yukesaier A; Lu L; Aierken K; Mijiti P; Jiang Y; Abulizi A; Zhang Y; Abuduxikuer G; Abulizi G; Li H
    Oncologist; 2016 Jul; 21(7):825-31. PubMed ID: 27317575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of The Cervista HPV A9 group In Screening Patients for Cervical Cancer.
    Zhao J; Du H; Belinson JL; Qu X; Zhang W; Mei J; Yang B; Wang C; Zhang L; Wu R
    J Med Screen; 2016 Mar; 23(1):38-43. PubMed ID: 26466824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology.
    Kurian EM; Caporelli ML; Baker S; Woda B; Cosar EF; Hutchinson L
    Am J Clin Pathol; 2011 Nov; 136(5):808-16. PubMed ID: 22031321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
    De Francesco MA; Gargiulo F; Schreiber C; Ciravolo G; Salinaro F; Manca N
    J Virol Methods; 2008 Jan; 147(1):10-7. PubMed ID: 17854914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical performance of Cervista HPV 16/18 genotyping test for cervical cytology samples.
    Bartholomew DA; Luff RD; Quigley NB; Curtis M; Olson MC
    J Clin Virol; 2011 May; 51(1):38-43. PubMed ID: 21376660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
    Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
    J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Testing of a new probe 16/18/45 Hybrid Capture (Digene) in women with high risk HPV infection].
    Hantz S; Decroisette E; Caly H; Renaudie J; Dussartre C; Bakeland D; Denis F; Alain S
    Pathol Biol (Paris); 2009 Feb; 57(1):81-5. PubMed ID: 18824308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate of detection of high-risk HPV with two assays in women ≥ 30 years of age.
    Quigley NB; Potter NT; Chivukula M; Knight MZ; Welch JR; Olson MC
    J Clin Virol; 2011 Sep; 52(1):23-7. PubMed ID: 21724457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
    Tiews S; Steinberg W; Schneider W; Hanrath C
    J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens.
    Youens KE; Hosler GA; Washington PJ; Jenevein EP; Murphy KM
    J Mol Diagn; 2011 Mar; 13(2):160-6. PubMed ID: 21354050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of prior cervical cytology and HR-HPV testing in women subsequently diagnosed with CIN1, CIN2/3, and invasive cervical cancer: a 4-year routine clinical experience after implementation of systematic training and quality control programs.
    Zhao D; Zhang L; Xie F; Peng D; Wei J; Jiang L; Zhang S; Qi D
    BMC Cancer; 2020 Aug; 20(1):810. PubMed ID: 32847541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance and Diagnostic Accuracy of Human Papillomavirus Testing on Self-Collected Urine and Vaginal Samples in a Referral Population.
    Cho HW; Hong JH; Min KJ; Ouh YT; Seong SJ; Moon JH; Cho SH; Lee JK
    Cancer Res Treat; 2021 Jul; 53(3):829-836. PubMed ID: 33421987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.